KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Gains from Investment Securities (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Gains from Investment Securities data on record, last reported at -$11.0 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 125.7% year-over-year to -$11.0 million; the TTM value through Dec 2025 reached -$5.5 million, down 23.85%, while the annual FY2025 figure was -$5.5 million, 23.85% down from the prior year.
  • Gains from Investment Securities reached -$11.0 million in Q4 2025 per PCRX's latest filing, down from $8000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $26.6 million in Q3 2022 and bottomed at -$22.4 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is -$552333.3, with a median of $10000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: plummeted 2138.24% in 2022, then soared 7050.0% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $1.2 million in 2021, then plummeted by 451.33% to -$4.2 million in 2022, then surged by 110.03% to $423000.0 in 2023, then crashed by 1251.54% to -$4.9 million in 2024, then plummeted by 125.7% to -$11.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$11.0 million in Q4 2025, $8000.0 in Q3 2025, and $5.2 million in Q2 2025.